HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Simon Tate Selected Research

vixotrigine

9/2020Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.
1/2020Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers.
1/2020Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia.
12/2018Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience.
4/2017Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
11/2013Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Simon Tate Research Topics

Disease

8Pain (Aches)
01/2023 - 01/2002
6Trigeminal Neuralgia (Tic Douloureux)
09/2020 - 11/2013
5Neuralgia (Stump Neuralgia)
09/2020 - 04/2002
1Cardiac Arrhythmias (Arrythmia)
09/2020
1Epilepsy (Aura)
09/2020
1Headache (Headaches)
04/2017
1Tremor (Tremors)
04/2017
1Fever (Fevers)
04/2017
1Dizziness (Lightheadedness)
04/2017
1Vomiting
04/2017
1Sleep Wake Disorders
04/2017
1Nasopharyngitis
04/2017
1Intractable Pain
02/2014
1Inflammation (Inflammations)
12/2006
1Hypersensitivity (Allergy)
12/2006
1Neuroblastoma
03/2004
1Sciatica (Sciatic Neuralgia)
01/2002
1Back Pain (Backache)
01/2002

Drug/Important Bio-Agent (IBA)

6vixotrigineIBA
09/2020 - 11/2013
5Voltage-Gated Sodium ChannelsIBA
09/2020 - 01/2002
3Analgesics (Analgesic Drugs)IBA
01/2023 - 01/2009
3Sodium Channel BlockersIBA
09/2020 - 11/2013
3Carbamazepine (Tegretol)FDA LinkGeneric
01/2020 - 11/2013
2Oxcarbazepine (Trileptal)FDA LinkGeneric
04/2017 - 11/2013
2Nerve Growth Factor (NGF)IBA
02/2014 - 12/2006
1Voltage-Gated Sodium Channel BlockersIBA
09/2020
1Anesthetics (Anesthetic Agents)IBA
09/2020
1Cytochrome P-450 CYP3AIBA
01/2020
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
02/2014
1Phosphotransferases (Kinase)IBA
02/2014
1Biomarkers (Surrogate Marker)IBA
02/2014
1Transient Receptor Potential ChannelsIBA
01/2009
1Capsaicin (Zostrix)FDA Link
12/2006
1Dinoprostone (PGE2)FDA Link
12/2006
1Freund's AdjuvantIBA
12/2006
1BradykininIBA
12/2006
1Interleukin-1beta (Interleukin 1 beta)IBA
12/2006

Therapy/Procedure

1Activities of Daily Living (ADL)
11/2013
1Axotomy
04/2002
1Therapeutics
01/2002